Esperion Therapeutics Inc
ESPR3.690USD
+0.520+16.40%
Close 11/25, 16:00（ET）Quotes delayed by 15 min
758.04MMarket Cap
LossP/E TTM
More Details of Esperion Therapeutics Inc Company
Esperion Therapeutics, Inc. is a pharmaceutical company. The Company is focused on developing and commercializing oral, once-daily, non-statin medicines for patients struggling with elevated low-density lipoprotein cholesterol (LDL-C). The Company's products include NEXLETOL, NEXLIZET, NILEMDO and NUSTENDI. The Company's NEXLETOL and NEXLIZET (bempedoic acid and ezetimibe) tablets are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia (HeFH) or atherosclerotic cardiovascular disease (ASCVD). Its NEXLETOL is an ATP Citrate Lyase (ACL), inhibitor that lowers LDL-C by reducing cholesterol biosynthesis and up-regulating the LDL receptors. Its NUSTENDI contains bempedoic acid and ezetimibe and lowers elevated LDL-C through complementary mechanisms of action by inhibiting cholesterol synthesis in the liver and absorption in the intestine. Its Pipeline product include Next Generation ACLYi.
Esperion Therapeutics Inc Info
Ticker SymbolESPR
Company nameEsperion Therapeutics Inc
IPO dateJun 24, 2013
CEOMr. Sheldon L. Koenig
Number of employees304
Security typeOrdinary Share
Fiscal year-endJun 24
Address3891 Ranchero Drive, Suite 150
CityANN ARBOR
Stock exchangeNASDAQ Global Market Consolidated
CountryUnited States of America
Postal code48108
Phone17348873903
Websitehttps://www.esperion.com/
Ticker SymbolESPR
IPO dateJun 24, 2013
CEOMr. Sheldon L. Koenig
Company Executives of Esperion Therapeutics Inc
Name
Name/Position
Position
Shareholding
Change
Mr. Sheldon L. Koenig
Mr. Sheldon L. Koenig
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
249.81K
-10.22%
Mr. Benjamin (Ben) Halladay
Mr. Benjamin (Ben) Halladay
Chief Financial Officer
Chief Financial Officer
76.46K
-8.44%
Mr. Stephen C. Rocamboli, J.D.
Mr. Stephen C. Rocamboli, J.D.
Independent Director
Independent Director
69.26K
+91.01%
Ms. Tracy M. Woody
Ms. Tracy M. Woody
Independent Director
Independent Director
33.57K
--
Mr. Robert E. Hoffman, CPA
Mr. Robert E. Hoffman, CPA
Independent Director
Independent Director
5.28K
--
Mr. Seth H. Z. Fischer
Mr. Seth H. Z. Fischer
Independent Director
Independent Director
--
--
Ms. Alina Venezia
Ms. Alina Venezia
IR Contact Officer
IR Contact Officer
--
--
Mr. J. Martin (Marty) Carroll
Mr. J. Martin (Marty) Carroll
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Mr. Benjamin O. Looker, Esq.
Mr. Benjamin O. Looker, Esq.
General Counsel
General Counsel
--
--
Mr. Jay P. Shepard
Mr. Jay P. Shepard
Independent Director
Independent Director
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Mr. Sheldon L. Koenig
Mr. Sheldon L. Koenig
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
249.81K
-10.22%
Mr. Benjamin (Ben) Halladay
Mr. Benjamin (Ben) Halladay
Chief Financial Officer
Chief Financial Officer
76.46K
-8.44%
Mr. Stephen C. Rocamboli, J.D.
Mr. Stephen C. Rocamboli, J.D.
Independent Director
Independent Director
69.26K
+91.01%
Ms. Tracy M. Woody
Ms. Tracy M. Woody
Independent Director
Independent Director
33.57K
--
Mr. Robert E. Hoffman, CPA
Mr. Robert E. Hoffman, CPA
Independent Director
Independent Director
5.28K
--
Mr. Seth H. Z. Fischer
Mr. Seth H. Z. Fischer
Independent Director
Independent Director
--
--
Revenue Breakdown
Relevant data have not been disclosed by the company yet.
Relevant data have not been disclosed by the company yet.
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Mon, Nov 17
Updated: Mon, Nov 17
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
BlackRock Institutional Trust Company, N.A.
5.64%
The Vanguard Group, Inc.
5.06%
Two Seas Capital LP
4.08%
Wasatch Global Investors Inc
2.95%
PenderFund Capital Management, Ltd.
2.79%
Other
79.48%
Shareholders
Shareholders
Proportion
BlackRock Institutional Trust Company, N.A.
5.64%
The Vanguard Group, Inc.
5.06%
Two Seas Capital LP
4.08%
Wasatch Global Investors Inc
2.95%
PenderFund Capital Management, Ltd.
2.79%
Other
79.48%
Shareholder Types
Shareholders
Proportion
Investment Advisor
20.90%
Investment Advisor/Hedge Fund
12.39%
Hedge Fund
8.62%
Research Firm
3.75%
Private Equity
0.93%
Individual Investor
0.44%
Venture Capital
0.31%
Bank and Trust
0.18%
Pension Fund
0.12%
Other
52.35%
Institutional Shareholding
Updated: Wed, Oct 1
Updated: Wed, Oct 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q3
367
106.12M
44.40%
-48.67M
2025Q2
382
118.70M
59.89%
-48.77M
2025Q1
406
120.12M
60.62%
-48.61M
2024Q4
416
132.03M
67.01%
-41.92M
2024Q3
411
131.82M
67.24%
-43.99M
2024Q2
396
139.50M
73.71%
-8.75M
2024Q1
381
127.67M
67.51%
+27.09M
2023Q4
370
73.40M
64.38%
-30.67M
2023Q3
392
79.14M
69.19%
-24.19M
2023Q2
397
76.08M
79.96%
-27.32M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
BlackRock Institutional Trust Company, N.A.
13.45M
6.67%
+118.96K
+0.89%
Jun 30, 2025
The Vanguard Group, Inc.
11.72M
5.81%
+229.10K
+1.99%
Jun 30, 2025
Two Seas Capital LP
9.95M
4.94%
+3.02M
+43.63%
Jun 30, 2025
Wasatch Global Investors Inc
10.34M
5.13%
-591.00K
-5.41%
Jun 30, 2025
PenderFund Capital Management, Ltd.
6.68M
3.31%
+4.68M
+233.83%
Jun 30, 2025
Geode Capital Management, L.L.C.
4.58M
2.27%
+137.69K
+3.10%
Jun 30, 2025
State Street Investment Management (US)
3.76M
1.86%
-789.53K
-17.36%
Jun 30, 2025
Two Sigma Investments, LP
3.92M
1.95%
-1.34M
-25.42%
Jun 30, 2025
Meditor Capital Management Limited
3.79M
1.88%
--
--
Sep 30, 2024
View more
Related ETFs
Updated: Thu, Nov 6
Updated: Thu, Nov 6
Name
Proportion
SPDR S&P Pharmaceuticals ETF
0.83%
Direxion Daily Pharmaceutical & Medical Bl 3X ETF
0.62%
Invesco NASDAQ Future Gen 200 ETF
0.58%
VictoryShares Small Cap Free Cash Flow ETF
0.3%
iShares Micro-Cap ETF
0.1%
ProShares Ultra Nasdaq Biotechnology
0.06%
Invesco Nasdaq Biotechnology ETF
0.06%
Principal U.S. Small-Cap ETF
0.05%
Invesco RAFI US 1500 Small-Mid ETF
0.05%
Vanguard US Momentum Factor ETF
0.04%
View more
SPDR S&P Pharmaceuticals ETF
Proportion0.83%
Direxion Daily Pharmaceutical & Medical Bl 3X ETF
Proportion0.62%
Invesco NASDAQ Future Gen 200 ETF
Proportion0.58%
VictoryShares Small Cap Free Cash Flow ETF
Proportion0.3%
iShares Micro-Cap ETF
Proportion0.1%
ProShares Ultra Nasdaq Biotechnology
Proportion0.06%
Invesco Nasdaq Biotechnology ETF
Proportion0.06%
Principal U.S. Small-Cap ETF
Proportion0.05%
Invesco RAFI US 1500 Small-Mid ETF
Proportion0.05%
Vanguard US Momentum Factor ETF
Proportion0.04%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
FAQs
Who are the top five shareholders of Esperion Therapeutics Inc?
The top five shareholders of Esperion Therapeutics Inc are:
BlackRock Institutional Trust Company, N.A. holds 13.45M shares, accounting for 6.67% of the total shares.
The Vanguard Group, Inc. holds 11.72M shares, accounting for 5.81% of the total shares.
Two Seas Capital LP holds 9.95M shares, accounting for 4.94% of the total shares.
Wasatch Global Investors Inc holds 10.34M shares, accounting for 5.13% of the total shares.
PenderFund Capital Management, Ltd. holds 6.68M shares, accounting for 3.31% of the total shares.
BlackRock Institutional Trust Company, N.A. holds 13.45M shares, accounting for 6.67% of the total shares.
The Vanguard Group, Inc. holds 11.72M shares, accounting for 5.81% of the total shares.
Two Seas Capital LP holds 9.95M shares, accounting for 4.94% of the total shares.
Wasatch Global Investors Inc holds 10.34M shares, accounting for 5.13% of the total shares.
PenderFund Capital Management, Ltd. holds 6.68M shares, accounting for 3.31% of the total shares.
What are the top three shareholder types of Esperion Therapeutics Inc?
The top three shareholder types of Esperion Therapeutics Inc are:
BlackRock Institutional Trust Company, N.A.
The Vanguard Group, Inc.
Two Seas Capital LP
BlackRock Institutional Trust Company, N.A.
The Vanguard Group, Inc.
Two Seas Capital LP
How many institutions hold shares of Esperion Therapeutics Inc (ESPR)?
As of 2025Q3, 367 institutions hold shares of Esperion Therapeutics Inc, with a combined market value of approximately 106.12M, accounting for 44.40% of the total shares. Compared to 2025Q2, institutional shareholding has increased by -15.49%.
What is the biggest source of revenue for Esperion Therapeutics Inc?
In --, the -- business generated the highest revenue for Esperion Therapeutics Inc, amounting to -- and accounting for --% of total revenue.
